Clinic
Riviera Medical Corporation
Riviera Medical Corporation was paid $1.23M by Medicaid between Jul 2020 and Dec 2024, across 18 billing codes. Its largest line is 87635, Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe — 26% of everything it billed.
33Billing provider infoRIVIERA MEDICAL CORPORATION
NEWPORT BEACH, CA 92660
NEWPORT BEACH, CA 92660
33aNPI1225224389assigned 09/21/2007
33bProvider typeUrgent Care Clinic/Center
28Total paid$1.23M
24GClaims54,981
24DCodes billed18
24AFirst – last monthJul 2020 – Dec 2024
Compared with peers
Next to other Urgent Care Clinic/Center providers in California
Rank by total paid#72 of 284
Median peer was paid$147K
This provider vs. median8.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 708 | $16K | |
| 2021 | 17,251 | $484K | |
| 2022 | 12,576 | $294K | |
| 2023 | 6,671 | $107K | |
| 2024incomplete | 17,775 | $326K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 26% | 10,962 | 4,641 | $322K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 22% | 9,498 | 7,786 | $267K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 13% | 5,123 | 5,035 | $157K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 12% | 7,640 | 6,581 | $147K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 10.0% | 6,094 | 4,919 | $123K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 8.0% | 12,672 | 4,700 | $97K |
| 87631 | 4.1% | 1,121 | 560 | $50K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.8% | 216 | 188 | $23K |
| 86328 | 1.1% | 332 | 323 | $13K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.0% | 882 | 597 | $12K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | <1% | 176 | 176 | $8K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | <1% | 56 | 55 | $2K |
6 more codes
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 33 | $1K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 66 | $1K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 24 | $982.08 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 33 | $386.16 |
| 99307 | <1% | 24 | $328.80 | |
| 99072 | 0% | 29 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDOONAN, BRYAN (PRESIDENT)